| Date | Title | Description |
| 10.09.2026 | PW Consulting: Global Sedative-Hypnotic Drug Market Hits $4.85B in 2025, Projected 5.85% CAGR to 2032 | Navigating the Global Sedative-Hypnotic Drug Market: Strategic Imperatives for 2026 and Beyond
The global healthcare landscape is undergoing a significant transformation, driven by an aging population, increasing prevalence of sleep disorde... |
| 01.09.2026 | Canada’s Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi® | Canada’s Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
Tue, Sep 01, 2026 07:00 CET Report this content
Stockholm, Sweden, September 1, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) pa... |
| 31.08.2026 | Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 | Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
Mon, Aug 31, 2026 17:30 CET Report this content
Stockholm, August 31, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,2... |
| 26.08.2026 | Interim Report for the period April – June 2026 | Interim Report for the period April – June 2026
Wed, Aug 26, 2026 08:00 CET Report this content
New approvals for Leqembi® and additional strategic partnerships
Events during the second quarter 2026 Eisai provided a sales forecast for Leqem... |
| 25.08.2026 | Fosun Pharma Announces 2026 Interim Results | Globalization Accelerates Value Realization of Innovative Drugs
SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the fir... |
| 24.08.2026 | Leqembi Iqlik® for initiation treatment launched in the US | Leqembi Iqlik® for initiation treatment launched in the US
Mon, Aug 24, 2026 14:05 CET Report this content
Stockholm, Sweden, August 24, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that lecanemab-ir... |
| 19.08.2026 | BioArctic and Mesenkia enter oncology research collaboration | BioArctic and Mesenkia enter oncology research collaboration
Wed, Aug 19, 2026 11:15 CET Report this content
Stockholm, Sweden, August 19, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and Mesenkia Therapeutics announced today that ... |
| 19.08.2026 | Invitation to presentation of BioArctic’s second quarter report for April – June 2026 on August 26 at 9:30 a.m. CEST | Invitation to presentation of BioArctic’s second quarter report for April – June 2026 on August 26 at 9:30 a.m. CEST
Wed, Aug 19, 2026 08:30 CET Report this content
Stockholm, Sweden, August 19, 2026 – BioArctic AB (publ) (Nasdaq Stockholm:... |
| 29.07.2026 | Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 | Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
Wed, Jul 29, 2026 12:00 CET Report this content
Stockholm, Sweden, July 29, 2026 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the prel... |
| 29.07.2026 | Alzheimer’s Third Lesion Named: Mitochondrial Plaques Explain Why Anti-Amyloid Drugs Fall Short | By Morris Robinson
Published: Jul 29 2026, 11:14 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 15.07.2026 | Минздрав впервые зарегистрировал препарат по итогам инспекции за рубежом | Минздрав впервые зарегистрировал препарат по итогам инспекции за рубежом Eisai получила регудостоверение, хотя не проводила клинисследований в России
Японская фармкомпания Eisai 1 июля получила регудостоверение на свой новый препарат против... |
| 14.07.2026 | PMN310 Cuts Alzheimer Oligomers in Humans, Dodging Side Effects That Limit Rival Drugs | By Frederick Rodriguez
Published: Jul 14 2026, 3:24 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 14.07.2026 | More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 | More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
Tue, Jul 14, 2026 17:15 CET Report this content
Stockholm, S... |
| 13.07.2026 | FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer’s disease | FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer’s disease
Mon, Jul 13, 2026 23:55 CET Report this content
Stockholm, Sweden, July 13, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm:... |
| 12.07.2026 | New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer’s disease | New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer’s disease
Sun, Jul 12, 2026 17:30 CET Report this content
Stockholm, Sweden, July 1... |
| 10.07.2026 | Alzheimer’s Conference Opens Sunday as Lecanemab’s Real-World Test Arrives | By Mike Gonzales
Published: Jul 10 2026, 4:21 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 30.06.2026 | New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 | New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026
Tue, Jun 30, 2026 08:00 CET Report this content
Stockholm, Sweden, June 30, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will... |
| 22.06.2026 | BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology | BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology
Mon, Jun 22, 2026 07:32 CET Report this content
Stockholm, Sweden, June 22, 2026 – BioArctic AB (publ) (Nas... |
| 13.06.2026 | Starmer agrees investment deal with Japan as EU deal questioned | The UK government has agreed an £18bn investment deal with Japan in a bid to boost post-Brexit international ties but questions are now looming over Sir Keir Starmer’s “reset” deal with the EU.
Starmer said “landmark agreements” with Japan ... |
| 11.06.2026 | Beren Therapeutics Secures $300 Million Financing To Support Potential Adrabetadex Launch | Beren Therapeutics announced a combined $300 million financing package to support the potential commercial launch of adrabetadex and expand long-term patient access and family support initiatives for infantile-onset Niemann-Pick disease typ... |
| 10.06.2026 | Beren Therapeutics Raises $300M in Combined Equity and Debt Financing | Beren Therapeutics, a Thousand Oaks, California-based developer of cyclodextrin-based cholesterol trafficking therapeutics, raised $300m in a combined equity and debt financing round.
The round consisted of:
a $135m equity tranche backed by... |
| 29.05.2026 | Number of shares and votes in BioArctic AB (publ) as of May 29, 2026 | Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
Fri, May 29, 2026 18:30 CET Report this content
Stockholm, May 29, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Clas... |
| 28.05.2026 | Bulletin from the Annual General Meeting in BioArctic AB (publ) | Bulletin from the Annual General Meeting in BioArctic AB (publ)
Thu, May 28, 2026 18:30 CET Report this content
Stockholm, 28 May 2026. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, wher... |
| 26.05.2026 | Game-changing accelerator which has helped life science start-ups raise £120m welcomes new cohort | Six exciting early-stage ventures secure coveted spots on Babraham Research Campus’ Accelerate@Babraham pre-seed company support programme.
Cambridge, UK, 26th May 2026: Babraham Research Campus is delighted to announce the 2026 Accelerate@... |
| 25.05.2026 | BioArctic’s partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day | BioArctic’s partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
Mon, May 25, 2026 09:15 CET Report this content
Stockholm, Sweden, May 25, 2026 – BioArctic AB’s (publ) (Nasdaq Stockhol... |
| 20.05.2026 | Interim Report for the period January – March 2026 | Interim Report for the period January – March 2026
Wed, May 20, 2026 07:00 CET Report this content
Strong financial performance with commercial milestone reached
Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation... |
| 13.05.2026 | Invitation to presentation of BioArctic’s first quarter report for January – March 2026 on May 20 at 9:30 a.m. CET | Invitation to presentation of BioArctic’s first quarter report for January – March 2026 on May 20 at 9:30 a.m. CET
Wed, May 13, 2026 08:30 CET Report this content
Stockholm, Sweden, May 13, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA... |
| 08.05.2026 | Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. | Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
Fri, May 08, 2026 08:30 CET Report this content
Stockholm, Sweden, May 8, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food a... |
| 29.04.2026 | Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million | Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors
SHANGHAI, April 29, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biote... |
| 28.04.2026 | Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution | SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Compa... |
| 21.04.2026 | Tortugas Neuroscience Raises $106M in Seed and Series A Funding | Tortugas Neuroscience, a Framingham, MA-based neurology-focused biotech company developing novel medicines with derisked mechanisms of actions, for large and well-defined indications, raised $106M in Seed and Series A financings.
Cure Ventu... |
| 27.03.2026 | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Fri, Mar 27, 2026 08:00 CET Report this content
Stockholm March 27, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) her... |
| 23.03.2026 | New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress | New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
Mon, Mar 23, 2026 08:30 CET Report this content
Stockholm, Sweden, March 23, 2026 – BioArctic’s AB (publ) (Nasdaq Stockholm: BIOA B) partner Ei... |
| 22.03.2026 | Excalipoint Therapeutics Secures $68.7M for Next-Gen TCE Therapies | Excalipoint Therapeutics, a dynamic Shanghai-based biotechnology firm, secured $68.7 million in oversubscribed seed funding. This substantial capital propels its mission to redefine T-cell engager (TCE) therapies. The company is tackling si... |
| 18.03.2026 | Demeetra Announces Renewal of piggyBac® Technology Research License by Eisai
USA - English USA - English | Demeetra AgBio, Inc. (hereafter "Demeetra") today announced that the renewal of the research license agreement for the piggyBac® transposase technology, a widely used platform for genetic engineering in research applications, by E... |
| 18.03.2026 | Excalipoint Therapeutics Raises $68.7M in Seed Funding | Excalipoint Therapeutics, a Shanghai, China-based biotechnology company developing T-cell engager (TCE) therapies for cancer and autoimmune diseases, raised $68.7M in Seed funding.
Backers included HSG, Apricot Capital, Yuanbio Venture Capi... |
| 18.03.2026 | Excalipoint Therapeutics: $68.7 Million Raised For Next-Generation T-Cell Engager Therapies | Excalipoint Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell engager therapies, announced the close of an oversubscribed $68.7 million seed financing round to advance its proprietary platforms and pipel... |
| 11.03.2026 | Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress | Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
Wed, Mar 11, 2026 08:00 CET Report this content
Stockholm, Sweden, March 11, 2026 – BioArctic’s AB (publ) (Nasdaq Stockholm: BIOA B)... |
| 27.02.2026 | Number of shares and votes in BioArctic AB (publ) as of February 27, 2026 | Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
Fri, Feb 27, 2026 18:30 CET Report this content
Stockholm, February 27, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued ... |
| 21.02.2026 | Sift Biosciences Raises $3.7 Million Pre-Seed To Advance T-Cell Booster Platform | Sift Biosciences has closed an oversubscribed $3.7 million pre-seed financing round to accelerate development of its next-generation peptide immunotherapy platform designed to activate pre-existing memory T cells. The round was co-led by Fr... |
| 19.02.2026 | Sift Biosciences Raises $3.7M in Pre-Seed Funding | Sift Biosciences, a San Carlos, CA-based provider of a peptide-based immunotherapy platform, raised $3.7M in Pre-Seed funding.
The round was co-led by Lifespan Vision Ventures and Freeflow Ventures, with participation from Valuence Ventures... |
| 19.02.2026 | Lifespan Vision Ventures Co-Leads Sift Biosciences' $3.7M Pre-Seed Financing | NORWALK, Conn., Feb. 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it has co-led Sift Biosciences' oversubscribed $3.7 million Pre-Seed fina... |
| 18.02.2026 | Interim Report for the period October – December 2025 | Interim Report for the period October – December 2025
Wed, Feb 18, 2026 08:00 CET Report this content
A transformative year with record financial results
Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintena... |
| 17.02.2026 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00... |
| 11.02.2026 | Invitation to presentation of BioArctic’s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET
Wed, Feb 11, 2026 08:30 CET Report this content
Stockholm, Sweden, February 11, 2026 – BioArctic AB (publ) (Nasdaq S... |
| 09.02.2026 | BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China | BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
Mon, Feb 09, 2026 06:45 CET Report this content
Stockholm, Sweden, February 9, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 06.02.2026 | Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 | Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Fri, Feb 06, 2026 12:00 CET Report this content
Stockholm, Sweden, February 6, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the p... |
| 05.02.2026 | Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan | TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced to... |
| 03.02.2026 | Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai | TOKYO, Feb. 3, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million1) in six R&D projects for the development of drugs, diagnostic... |
| 26.01.2026 | Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) | Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
Mon, Jan 26, 2026 22:00 CET Report this content
Stockholm, Sweden, January 26, 2026 – BioArctic AB's (publ)... |
| 26.01.2026 | Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA | Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
Mon, Jan 26, 2026 00:30 CET Report this content
Stockholm, Sweden, January 26, 2026 – Bio... |
| 06.01.2026 | BLA for subcutaneous formulation of Leqembi® accepted in China | BLA for subcutaneous formulation of Leqembi® accepted in China
Tue, Jan 06, 2026 12:00 CET Report this content
Stockholm, Sweden, Januari 6, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biol... |
| 30.12.2025 | Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient | Novo Nordisk has had a difficult year as investors questioned the company’s ability to translate its strides in pioneering GLP-1 drugs to financial gains.
Scientists, however, say that Novo’s medicine still has potential.
What started with ... |
| 18.12.2025 | PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets | TOKYO, Dec. 18, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (... |
| 25.11.2025 | Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose | Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose
Tue, Nov 25, 2025 13:37 CET Report this content
Stockholm, Sweden, November 25, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm... |
| 24.11.2025 | Novo Nordisk shares plunge after Alzheimer’s drug trial fails to hit key target | Analysts had prior to the results called the trial a long shot, whereas Novo itself had referred to it as a “lottery ticket.”
The trial tested whether semaglutide — the active ingredient in Novo’s blockbuster diabetes and weight loss drugs ... |
| 14.11.2025 | PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. | TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved ... |
| 04.11.2025 | Invitation to presentation of BioArctic’s third quarter report for July – September 2025 on November 13 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s third quarter report for July – September 2025 on November 13 at 9.30 a.m. CET
Tue, Nov 04, 2025 10:00 CET Report this content
Stockholm, Sweden, November 3, 2025 – BioArctic AB (publ) (Nasdaq Stock... |
| 30.10.2025 | Sales of Leqembi® totaled 18 billion yen in the third quarter 2025 | Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
Thu, Oct 30, 2025 11:00 CET Report this content
Stockholm, Sweden, October 30, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the prel... |
| 27.10.2025 | Health Canada Grants Authorization for Leqembi® (lecanemab) | Health Canada Grants Authorization for Leqembi® (lecanemab)
Mon, Oct 27, 2025 00:35 CET Report this content
Stockholm, October 27, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has ... |
| 17.10.2025 | BioArctic presents Nomination Committee | BioArctic presents Nomination Committee
Fri, Oct 17, 2025 15:00 CET Report this content
Stockholm, Sweden, October 17, 2025 – Pursuant to the instruction regarding the appointment of the Nomination Committee, BioArctic AB (publ) (Nasdaq Sto... |
| 14.10.2025 | First patient treated with Leqembi® (lecanemab) in the Nordics | First patient treated with Leqembi® (lecanemab) in the Nordics
Tue, Oct 14, 2025 09:05 CET Report this content
Stockholm, October 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Leqembi has now been made avail... |
| 14.10.2025 | Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 | Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
Tue, Oct 14, 2025 07:00 CET Report this content
Stockholm, October 14, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced ... |
| 06.10.2025 | Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. | Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
Mon, Oct 06, 2025 22:35 CET Report this content
Stockholm, October 6, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lec... |
| 30.09.2025 | James Mackay is tending to 'unfinished business' with new gout biotech and $205M fundraise | In this market, three things make fundraising easier for a biotech: a derisked asset touting a well-defined profile and an experienced team to guide the program’s development.
Crystalys Therapeutics has checked all three boxes, proving that... |
| 24.09.2025 | Leqembi® approved for the treatment of early Alzheimer’s disease in Australia | Leqembi® approved for the treatment of early Alzheimer’s disease in Australia
Wed, Sep 24, 2025 08:40 CET Report this content
Stockholm, September 24, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeu... |
| 09.09.2025 | Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 | Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
Tue, Sep 09, 2025 09:05 CET Report this content
Stockholm, Sweden, September 9, 2025 – Uppsala University announced today that BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA... |
| 04.09.2025 | AI Governance as Competitive Capability: The Pioneering Work of Sumesh Nair in Biopharma | Created by Carl Williams
Published: Sep 04 2025, 00:41 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 03.09.2025 | Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status | Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status
Wed, Sep 03, 2025 01:30 CET Report this content
Stockholm, Se... |
| 03.09.2025 | BioArctic’s founders intend to divest minor part of their shareholding | BioArctic’s founders intend to divest minor part of their shareholding
Wed, Sep 03, 2025 17:35 CET Report this content
Stockholm, September 3, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been made aware that the company’s two ... |
| 01.09.2025 | Number of shares and votes in BioArctic AB (publ) as of August 29, 2025 | Number of shares and votes in BioArctic AB (publ) as of August 29, 2025
Mon, Sep 01, 2025 18:30 CET Report this content
Stockholm, September 1, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 10... |
| 29.08.2025 | US FDA approves Leqembi® IQLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease | US FDA approves Leqembi® IQLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease
Fri, Aug 29, 2025 23:55 CET Report this content
Stockholm, August 29, 2025 – BioArctic AB’s (publ... |
| 28.08.2025 | Interim Report for the period April – June 2025 | Interim Report for the period April – June 2025
Thu, Aug 28, 2025 08:00 CET Report this content
Increasing Leqembi® royalties and new partnership with Novartis
Events during the second quarter 2025 The European Commission granted Marketing ... |
| 26.08.2025 | BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties | BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
Tue, Aug 26, 2025 07:05 CET Report this content
S... |
| 25.08.2025 | Leqembi® (lecanemab) launched in the EU today | Leqembi® (lecanemab) launched in the EU today
Mon, Aug 25, 2025 09:00 CET Report this content
Stockholm, August 25, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the launch of Leqembi in the EU s... |
| 21.08.2025 | Invitation to presentation of BioArctic’s second quarter report for April – June 2025 on August 28 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s second quarter report for April – June 2025 on August 28 at 9.30 a.m. CET
Thu, Aug 21, 2025 09:00 CET Report this content
Stockholm, Sweden, August 21, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: ... |
| 21.08.2025 | Availity Invests $4.3 Million to Set Up New GCC in Bengaluru, Steps Up Hiring The company's India GCC workforce doubled in 2025, with year-end headcount projected at 3.5 times of what it was in Januar... | Availity, US-based real-time health information network, has invested USD 4.3 million to expand its India operations by opening a 54,000 sq. ft. facility in Bengaluru, India. The facility marks a significant step in the evolution of Availit... |
| 13.08.2025 | India Witnesses a Fresh Wave of Marquee GCC Setups and Large-Scale Expansions in July Companies are doubling down on India's strategic value— driven by access to deep digital talent, operational resil... | India has witnessed a fresh wave of marquee global capability centre (GCC) setups and large-scale expansions in July strengthening its position as the global hub for GCCs.
"From Fortune 500 giants to emerging tech innovators, companies... |
| 06.08.2025 | Quantifying the ROI of Compliance: Sumesh Nair on Architecting Risk-Based AI Validation for Modern Clinical Trials | Share
Share
Share
Share
Email
For any new therapy to reach the patients who need it, it must first navigate a formidable and complex global regulatory landscape. In the life sciences industry, this landscape is built upon a foundational set... |
| 04.08.2025 | After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line? | Last month, Hengrui Pharmaceuticals announced a blockbuster licensing deal with GSK worth up to USD 12.5 billion, with an upfront payment of USD 500 million. The deal grants GSK the overseas rights to Hengrui’s HRS-9821 as well as exclusive... |
| 31.07.2025 | Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect with consistent safety profile | Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect with consistent safety profile
Thu, Jul 31, 2025 01:30 CET Report this content
Stockholm, Sweden, July 31, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) par... |
| 31.07.2025 | Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 | Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
Thu, Jul 31, 2025 12:00 CET Report this content
Stockholm, Sweden, July 31, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the prel... |
| 31.07.2025 | RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE | TORONTO, July 31, 2025 /PRNewswire/ -- New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other d... |
| 31.07.2025 | Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025 | Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side effects of Alzheimer's disease treatments
Engaged in partnering with global big pharma and neurology KOLs, seeking global development collaborat... |
| 22.07.2025 | Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 | Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
Tue, Jul 22, 2025 08:00 CET Report this content
Stockholm, Sweden, July 22, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the lat... |
| 16.07.2025 | The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association | The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
Wed, Jul 16, 2025 09:30 CET Report this content
Stockholm, Sweden, July 16, 2025– BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA... |
| 26.06.2025 | Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize | Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
Thu, Jun 26, 2025 10:15 CET Report this content
Stockholm, Sweden, June 26, 2025– BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's fou... |
| 13.06.2025 | BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review | BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review
Fri, Jun 13, 2025 08:00 CET Report this content
Stockholm, June 13, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the... |
| 04.06.2025 | BioArctic: A Beacon of Hope in Neurodegenerative Treatment | In the heart of Stockholm, BioArctic AB is charting a bold course through the murky waters of neurodegenerative diseases. The company recently held its Capital Markets Day, a gathering that felt more like a rallying cry than a corporate eve... |
| 02.06.2025 | BioArctic’s Capital Markets Day 2025 – entering a new era of growth | BioArctic’s Capital Markets Day 2025 – entering a new era of growth
Mon, Jun 02, 2025 10:30 CET Report this content
Stockholm, June 2, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today welcomes investors, analysts and financial me... |
| 30.05.2025 | Number of shares and votes in BioArctic AB (publ) as of May 30, 2025 | Number of shares and votes in BioArctic AB (publ) as of May 30, 2025
Fri, May 30, 2025 18:30 CET Report this content
Stockholm, May 30, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 3,000 Clas... |
| 28.05.2025 | China Approves New Insomnia Therapy From Japanese Drugmaker Eisai | (Yicai) May 28 -- China has approved the use of Dayvigo, a new insomnia therapy developed by Japanese pharmaceutical company Eisai.
Dayvigo can be used in China for the treatment of adults with insomnia, characterized by difficulties with s... |
| 23.05.2025 | Innovations in Oncology: A Look Ahead to ASCO 2025 | The American Society of Clinical Oncology (ASCO) Annual Meeting is a beacon for cancer research. This year, it shines brightly in Chicago from May 30 to June 3, 2025. The event promises a treasure trove of insights into groundbreaking thera... |
| 23.05.2025 | Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting | Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM
TOKYO, May 23, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company desig... |
| 22.05.2025 | BioArctic and Tubulis: Pioneering New Frontiers in Biopharma | In the ever-evolving landscape of biopharmaceuticals, two companies stand out: BioArctic and Tubulis. Both are making waves with innovative treatments that promise to change the game for patients suffering from neurodegenerative diseases an... |
| 22.05.2025 | Bulletin from the Annual General Meeting in BioArctic AB (publ) | Bulletin from the Annual General Meeting in BioArctic AB (publ)
Thu, May 22, 2025 18:18 CET Report this content
Stockholm, 22 May 2025. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today... |
| 22.05.2025 | Navigating Neurological Disease Biomarkers -- Progress, Learnings and Future Directions, Upcoming Webinar Hosted by Xtalks | www.olink.com
In this free webinar, learn about the impact of emerging biomarkers, including endothelial, metabolic, immune, and inflammatory markers on the diagnosis and treatment of neurological diseases. The featured speakers will discus... |
| 22.05.2025 | BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy | BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy
Thu, May 22, 2025 15:15 CET Report this content
Stockholm, May 22, 2025 – BioArctic AB (publ) (Nasdaq Stockhol... |
| 21.05.2025 | Interim Report for the period January – March 2025 | Interim Report for the period January – March 2025
Wed, May 21, 2025 08:00 CET Report this content
Leqembi approved in the EU and billion-dollar license agreement with Bristol Myers Squibb came into effect
Events during the first quarter 20... |
| 15.05.2025 | Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026) | Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026)
Thu, May 15, 2025 06:00 CET Report this content
Stockholm, Sweden, May 15, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
